Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

completed267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

NCT02914171
unknownphase_2

Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury

NCT04528550
completedphase_1

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells

NCT02549625

Clinical Trials (3)

Showing 3 of 3 trials
NCT02914171Phase 1

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

Completed
NCT04528550Phase 2

Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury

Unknown
NCT02549625Phase 1

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3